ImmunityBio, Inc.
8.22USD
-0.0900 (-1.08%)
Fetching financial statements from SEC filings…
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on IBRX.
| In $M except per-share | Q2 FY26 | Q1 FY26 | Q4 FY25* | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24* | Q3 FY24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 51 | 44 | 38 | 32 | 26 | 17 | 8 | 6 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 51 | 44 | 38 | 32 | 26 | 16 | 8 | 6 |
| Operating Income | -62 | -70 | -65 | -56 | -71 | -64 | -69 | -80 |
| Net Income | -230 | -633 | -62 | -67 | -93 | -130 | -59 | -86 |
| EPS (Diluted) | -$0.22 | -$0.62 | -$0.06 | -$0.07 | -$0.10 | -$0.15 | -$0.09 | -$0.14 |
* Derived period (computed from FY minus reported quarters). Source: SEC filings (EDGAR)